{
    "clinical_study": {
        "@rank": "104185", 
        "arm_group": {
            "arm_group_label": "treatment", 
            "arm_group_type": "No Intervention"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to assess whether dasatinib can be discontinued without\n      occurrence of molecular relapse in patients with chronic myeloid  leukemia  in chronic phase\n      in complete molecular remission(CMR) while on dasatinib."
        }, 
        "brief_title": "Dasatinib for Patients Achieving Complete Molecular Response for Cure D-NewS Trial", 
        "condition": "Myelogenous Leukemia, Chronic, Chronic Phase", 
        "condition_browse": {
            "mesh_term": [
                "Leukemia", 
                "Leukemia, Myeloid", 
                "Leukemia, Myelogenous, Chronic, BCR-ABL Positive", 
                "Leukemia, Myeloid, Chronic-Phase", 
                "Chronic Disease"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Newly diagnosed Chronic Myeloid Leukemia in the Chronic Phase\n\n          -  15 years old over.\n\n          -  ECOG performance status (PS) score 0-2.\n\n          -  Adequate organ function (hepatic, renal and lung).\n\n          -  Signed written informed consent.\n\n        Exclusion Criteria:\n\n          -  A case with the double cancer of the activity.\n\n          -  Women who are pregnant or breastfeeding.\n\n          -  female patient who there is not intention with an appropriate sterilization, or\n             cannot use it during a study entry period\n\n          -  Patients with complications or a history of severe or uncontrolled cardiovascular\n             failure following have a Myocardial infarction within 6 months have an Angina within\n             3 months have a Congestive heart failure within 3 months have a QTc interval of more\n             than 450msec at baseline\n\n          -  A serious uncontrolled medical disorder that would impair the ability of the subjects\n             to receive protocol therapy"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "15 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 11, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01887561", 
            "org_study_id": "KCSG-04"
        }, 
        "intervention": {
            "arm_group_label": "treatment", 
            "intervention_name": "dasatinib", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Dasatinib"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "June 24, 2013", 
        "location": {
            "contact": {
                "email": "ntakezak@tdmc.hosp.go.jp", 
                "last_name": "Naoki Takesako", 
                "phone": "+81(0) 42-526-5511"
            }, 
            "facility": {
                "address": {
                    "city": "Tachikawa city", 
                    "country": "Japan", 
                    "state": "Tokyo", 
                    "zip": "190-0014"
                }, 
                "name": "National Disaster Medical Center"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase\u2161Clinical Trial of Dasatinib for Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase and Stop Therapy After Achieving Complete Molecular Response for Cure D-NewS", 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Japan: Ministry of Health, Labor and Welfare", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "The overall probability of maintenance of complete molecular remission after stopping dasatinib as measured by RQ-PCR", 
            "safety_issue": "No", 
            "time_frame": "by 12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01887561"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Kanto CML Study Group", 
            "investigator_full_name": "Naoki Takezako, M.D., Ph.D.", 
            "investigator_title": "Kanto CML Study Group", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "'Dasatinib affects immunological responses, as measured by flow cytometry", 
                "safety_issue": "No", 
                "time_frame": "at 3,6,12,24 months"
            }, 
            {
                "measure": "Major Molecular Response(MMR) rate measured by RQ-PCR", 
                "safety_issue": "No", 
                "time_frame": "by 1 months, then every 6 months for 2 years"
            }, 
            {
                "measure": "Complete Cytogenetic Response (CCyR) rate", 
                "safety_issue": "No", 
                "time_frame": "by 6,12 months"
            }, 
            {
                "measure": "Progression free survival (PFS)", 
                "safety_issue": "No", 
                "time_frame": "Participants were followed for at least 2 years"
            }, 
            {
                "measure": "Number of Participants with Adverse Events as a Measure of Safety and Tolerability", 
                "safety_issue": "Yes", 
                "time_frame": "Participants were followed for at least 2 years"
            }, 
            {
                "measure": "The overall probability of maintenance of complete molecular remission after stopping dasatinib as measured by RQ-PCR", 
                "safety_issue": "No", 
                "time_frame": "by 3,6 months"
            }, 
            {
                "measure": "Molecular remission rate measured by PQ-PCR after dasatinib re-challenge in cases of molecular relapse", 
                "safety_issue": "No", 
                "time_frame": "by 12 months after molecular relapse"
            }, 
            {
                "measure": "Complete Molecular Response(CMR) rate measured by RQ-PCR", 
                "safety_issue": "No", 
                "time_frame": "by 1 months, then every 6 months for 2 years"
            }
        ], 
        "source": "Kanto CML Study Group", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Kanto CML Study Group", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2013"
    }
}